Cambridge Biologicals Co is established by Dr Chiwen Chang in 2018 to commercialise a project developed in the University. It is a first-in-class immunotherapy for inflammatory and angiogenesis related diseases like rheumatoid arthritis and cancers etc. It’s in an early stage of fundraising for pre-clinical and clinical trials.